Hengrui Medicine: SHR-4506 Injection Receives Approval for Clinical Drug Trial

Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for SHR-4506 injection, approving the clinical trial of the drug in advanced malignant tumors. SHR-4506 injection is a class 1 therapeutic biologic product independently developed by the company, and there are currently no similar drugs approved for market both domestically and internationally. The total research and development investment in this project is approximately 19.92 million yuan.